Molecular Profiling of Carcinoma of Unknown Primary and Correlation With Clinical Evaluation

• DOI: 10.1200/jco.2007.14.4378
• Publication Date: 2008-09-18T22:23:38Z
• Authors: Gauri R. Varadhac...; Dmitri Talantov; Martin N. Raber; Christina Meng; Kenneth R. Hess; Tim Jatkoe; Renato Lenzi; David R. Spigel; Yixin Wang; F. Anthony Greco; James L. Abbruzzese; John D. Hainsworth
• Keywords: Profiling (computer programming)

Purpose To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify tissue origin in patients with carcinoma unknown primary (CUP) site. Patients and Methods Diagnostic biopsy formalin-fixed, paraffin-embedded (FFPE) specimens from 120 CUP were collected retrospectively Sarah Cannon Research Institute, Nashville, TN, prospectively The University Texas M. D. Anderson Cancer Center, Houston, TX. Tissue assignments by correlated clinical pathologic features response therapy. Results was successfully performed 104 (87%), assigned 63 (61%). In remaining 41 (39%), molecular profiles not specific for six tumor types detectable this assay. tissues most commonly identified lung, pancreas, colon; these had consistent diagnoses. lung pancreas poor treatment. colon cancer better cancer–specific therapies than they did empiric therapy taxane/platinum regimens. ovarian atypical, widespread visceral metastases paucity overt peritoneal involvement. Conclusion This gene expression profiling feasible using FFPE putative 61% CUP. patients, compatible clinicopathologic Prospective studies which results are used direct indicated.